



UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 15 2010

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Anita Varma, Esq.  
Fish & Neave IP Group  
Ropes & Gray LLP  
One International Place  
Boston, Massachusetts 02110-2624

In Re: Patent Term Extension  
Application for  
U.S. Patent No. 6,355,245

Dear Ms. Varma :

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 6,355,245 for a period of 735 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to patent expiration dates.

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at [mary.till@uspto.gov](mailto:mary.till@uspto.gov).

  
Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Associate Commissioner  
for Patent Examination Policy

cc:      Office of Regulatory Policy  
          Food and Drug Administration  
          10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
          Silver Spring, MD 20993-0002

RE: SOLIRIS® (eculizumab)  
Docket No.: FDA-2007-E-0166

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM  
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 6,355,245  
(45) ISSUED : March 12, 2002  
(75) INVENTOR : Mark J. Evans et al.  
(73) PATENT OWNER : Alexion Pharmaceuticals, Inc.  
(95) PRODUCT : SOLIRIS® (eculizumab)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 6,355,245 based upon the regulatory review of the product SOLIRIS® (eculizumab) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 735 days

from March 12, 2019, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 11th day of June 2010.

David J. Kappos  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office